{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:51:06Z","timestamp":1793652666978,"version":"4.5.1"},"reference-count":243,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1038\/s41584-024-01188-4","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T15:51:25Z","timestamp":1732809085000},"page":"46-62","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["An update on autoantibodies in the idiopathic inflammatory myopathies"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7864-205X","authenticated-orcid":false,"given":"Nur Azizah","family":"Allameen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Isabel","family":"Ramos-Lisbona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7495-1429","authenticated-orcid":false,"given":"Lucy R.","family":"Wedderburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6068-9212","authenticated-orcid":false,"given":"Ingrid E.","family":"Lundberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9514-2455","authenticated-orcid":false,"given":"David A.","family":"Isenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,28]]},"reference":[{"key":"1188_CR1","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan, A. & Peter, J. B. Polymyositis and dermatomyositis (first of two parts). N. Engl. J. Med. 292, 344\u2013347 (1975).","journal-title":"N. Engl. J. Med."},{"key":"1188_CR2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJM197502202920807","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan, A. & Peter, J. B. Polymyositis and dermatomyositis (second of two parts). N. Engl. J. Med. 292, 403\u2013407 (1975).","journal-title":"N. Engl. J. Med."},{"key":"1188_CR3","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1056\/NEJM199111213252107","volume":"325","author":"MC Dalakas","year":"1991","unstructured":"Dalakas, M. C. Polymyositis, dermatomyositis, and inclusion-body myositis. N. Engl. J. Med. 325, 1487\u20131498 (1991).","journal-title":"N. Engl. J. Med."},{"key":"1188_CR4","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","volume":"14","author":"JE Hoogendijk","year":"2004","unstructured":"Hoogendijk, J. E. et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10\u201312 October 2003, Naarden, The Netherlands. Neuromuscul. Disord. 14, 337\u2013345 (2004).","journal-title":"Neuromuscul. Disord."},{"key":"1188_CR5","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1097\/00005792-199111000-00002","volume":"70","author":"LA Love","year":"1991","unstructured":"Love, L. A. et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 70, 360\u2013374 (1991).","journal-title":"Medicine"},{"key":"1188_CR6","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jaut.2019.04.001","volume":"101","author":"Z Betteridge","year":"2019","unstructured":"Betteridge, Z. et al. Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J. Autoimmun. 101, 48\u201355 (2019).","journal-title":"J. Autoimmun."},{"key":"1188_CR7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jaut.2017.06.007","volume":"84","author":"SL Tansley","year":"2017","unstructured":"Tansley, S. L. et al. Autoantibodies in juvenile-onset myositis: their diagnostic value and associated clinical phenotype in a large UK cohort. J. Autoimmun. 84, 55\u201364 (2017).","journal-title":"J. Autoimmun."},{"key":"1188_CR8","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","volume":"14","author":"NJ McHugh","year":"2018","unstructured":"McHugh, N. J. & Tansley, S. L. Autoantibodies in myositis. Nat. Rev. Rheumatol. 14, 290\u2013302 (2018).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1188_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/joim.12451","volume":"280","author":"Z Betteridge","year":"2016","unstructured":"Betteridge, Z. & McHugh, N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J. Intern. Med. 280, 8\u201323 (2016).","journal-title":"J. Intern. Med."},{"key":"1188_CR10","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41584-023-00967-9","volume":"19","author":"C Papadopoulou","year":"2023","unstructured":"Papadopoulou, C., Chew, C., Wilkinson, M. G. L., McCann, L. & Wedderburn, L. R. Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care. Nat. Rev. Rheumatol. 19, 343\u2013362 (2023).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1188_CR11","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1093\/rheumatology\/kes073","volume":"51","author":"Y Muro","year":"2012","unstructured":"Muro, Y., Ishikawa, A., Sugiura, K. & Akiyama, M. Clinical features of anti-TIF1-\u03b1 antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-\u03b3 or anti-mi-2 autoantibodies. Rheumatology 51, 1508\u20131513 (2012).","journal-title":"Rheumatology"},{"key":"1188_CR12","doi-asserted-by":"publisher","first-page":"6972","DOI":"10.3390\/jcm11236972","volume":"11","author":"HL Huang","year":"2022","unstructured":"Huang, H. L. et al. Coexistence of multiple myositis-specific antibodies in patients with idiopathic inflammatory myopathies. J. Clin. Med. 11, 6972 (2022).","journal-title":"J. Clin. Med."},{"key":"1188_CR13","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.semarthrit.2020.10.014","volume":"51","author":"L Gupta","year":"2021","unstructured":"Gupta, L., Naveen, R., Gaur, P., Agarwal, V. & Aggarwal, R. Myositis-specific and myositis-associated autoantibodies in a large Indian cohort of inflammatory myositis. Semin. Arthritis Rheum. 51, 113\u2013120 (2021).","journal-title":"Semin. Arthritis Rheum."},{"key":"1188_CR14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/joim.12524","volume":"280","author":"IE Lundberg","year":"2016","unstructured":"Lundberg, I. E., Miller, F. W., Tj\u00e4rnlund, A. & Bottai, M. Diagnosis and classification of idiopathic inflammatory myopathies. J. Intern. Med. 280, 39\u201351 (2016).","journal-title":"J. Intern. Med."},{"key":"1188_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/0090-1229(76)90145-8","volume":"5","author":"M Reichlin","year":"1976","unstructured":"Reichlin, M. & Mattioli, M. Description of a serological reaction characteristic of polymyositis. Clin. Immunol. Immunopathol. 5, 12\u201320 (1976).","journal-title":"Clin. Immunol. Immunopathol."},{"key":"1188_CR16","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1002\/art.24621","volume":"60","author":"S Sato","year":"2009","unstructured":"Sato, S. et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum. 60, 2193\u20132200 (2009).","journal-title":"Arthritis Rheum."},{"key":"1188_CR17","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1002\/art.21023","volume":"52","author":"S Sato","year":"2005","unstructured":"Sato, S. et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 52, 1571\u20131576 (2005).","journal-title":"Arthritis Rheum."},{"key":"1188_CR18","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/art.33403","volume":"64","author":"M Fujimoto","year":"2012","unstructured":"Fujimoto, M. et al. Myositis-specific anti-155\/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum. 64, 513\u2013522 (2012).","journal-title":"Arthritis Rheum."},{"key":"1188_CR19","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.1002\/art.22164","volume":"54","author":"IN Targoff","year":"2006","unstructured":"Targoff, I. N. et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 54, 3682\u20133689 (2006).","journal-title":"Arthritis Rheum."},{"key":"1188_CR20","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1002\/art.24547","volume":"60","author":"H Gunawardena","year":"2009","unstructured":"Gunawardena, H. et al. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum. 60, 1807\u20131814 (2009).","journal-title":"Arthritis Rheum."},{"key":"1188_CR21","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1002\/art.22862","volume":"56","author":"Z Betteridge","year":"2007","unstructured":"Betteridge, Z., Gunawardena, H., North, J., Slinn, J. & McHugh, N. Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis. Arthritis Rheum. 56, 3132\u20133137 (2007).","journal-title":"Arthritis Rheum."},{"key":"1188_CR22","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1093\/rheumatology\/kead400","volume":"63","author":"E Van Gompel","year":"2024","unstructured":"Van Gompel, E. et al. Autoantibodies against the melanoma differentiation-associated protein 5 in patients with dermatomyositis target the helicase domains. Rheumatology 63, 1466\u20131473 (2024).","journal-title":"Rheumatology"},{"key":"1188_CR23","first-page":"1549","volume":"83","author":"I Pinal-Fernandez","year":"2024","unstructured":"Pinal-Fernandez, I. et al. Pathological autoantibody internalisation in myositis. Ann. Rheum. Dis. 83, 1549\u20131560 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1188_CR24","doi-asserted-by":"publisher","first-page":"773352","DOI":"10.3389\/fimmu.2021.773352","volume":"12","author":"A Nombel","year":"2021","unstructured":"Nombel, A., Fabien, N. & Coutant, F. Dermatomyositis with anti-MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies. Front. Immunol. 12, 773352 (2021).","journal-title":"Front. Immunol."},{"key":"1188_CR25","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1093\/rheumatology\/keaa429","volume":"60","author":"G Mamyrova","year":"2021","unstructured":"Mamyrova, G. et al. Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America. Rheumatology 60, 1839\u20131849 (2021).","journal-title":"Rheumatology"},{"key":"1188_CR26","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1080\/14397595.2018.1452353","volume":"29","author":"M Ueki","year":"2019","unstructured":"Ueki, M. et al. Myositis-specific autoantibodies in Japanese patients with juvenile idiopathic inflammatory myopathies. Mod. Rheumatol. 29, 351\u2013356 (2019).","journal-title":"Mod. Rheumatol."},{"key":"1188_CR27","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/acr.22498","volume":"67","author":"NS Narang","year":"2015","unstructured":"Narang, N. S., Casciola-Rosen, L., Li, S., Chung, L. & Fiorentino, D. F. Cutaneous ulceration in dermatomyositis: association with anti-melanoma differentiation-associated gene 5 antibodies and interstitial lung disease. Arthritis Care Res. 67, 667\u2013672 (2015).","journal-title":"Arthritis Care Res."},{"key":"1188_CR28","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41584-023-01054-9","volume":"20","author":"X Lu","year":"2024","unstructured":"Lu, X., Peng, Q. & Wang, G. Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress. Nat. Rev. Rheumatol. 20, 48\u201362 (2024).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1188_CR29","doi-asserted-by":"publisher","first-page":"4821","DOI":"10.1093\/rheumatology\/keab108","volume":"60","author":"Y Yamasaki","year":"2021","unstructured":"Yamasaki, Y. et al. Clinical impact of myositis-specific autoantibodies on long-term prognosis of juvenile idiopathic inflammatory myopathies: multicentre study. Rheumatology 60, 4821\u20134831 (2021).","journal-title":"Rheumatology"},{"key":"1188_CR30","first-page":"246","volume":"42","author":"L Liu","year":"2024","unstructured":"Liu, L. et al. Predictors of mortality for dermatomyositis patients positive with anti-melanoma differentiation-related gene 5 and optimal treatment. Clin. Exp. Rheumatol. 42, 246\u2013252 (2024).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1188_CR31","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13075-023-03100-z","volume":"25","author":"H Wang","year":"2023","unstructured":"Wang, H. et al. Mortality risk in patients with anti-MDA5 dermatomyositis is related to rapidly progressive interstitial lung disease and anti-Ro52 antibody. Arthritis Res. Ther. 25, 127 (2023).","journal-title":"Arthritis Res. Ther."},{"key":"1188_CR32","first-page":"33","volume":"4","author":"S Bhandari","year":"2024","unstructured":"Bhandari, S. et al. A review of MDA-5 dermatomyositis and associated interstitial lung disease. Rheumatology 4, 33\u201348 (2024).","journal-title":"Rheumatology"},{"key":"1188_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003150","volume":"9","author":"X Chen","year":"2023","unstructured":"Chen, X. et al. Clinical, radiological and pathological features of anti-MDA5 antibody-associated interstitial lung disease. RMD Open\u00a09, e003150 (2023).","journal-title":"RMD Open"},{"key":"1188_CR34","first-page":"291","volume":"41","author":"T Shirai","year":"2023","unstructured":"Shirai, T., Machiyama, T., Sato, H., Ishii, T. & Fujii, H. Intensive induction therapy combining tofacitinib, rituximab and plasma exchange in severe anti-melanoma differentiation-associatedprotein-5 antibody-positive dermatomyositis. Clin. Exp. Rheumatol. 41, 291\u2013300 (2023).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1188_CR35","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/art.41105","volume":"72","author":"H Tsuji","year":"2020","unstructured":"Tsuji, H. et al. Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Arthritis Rheumatol. 72, 488\u2013498 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"1188_CR36","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/rheumatology\/kep375","volume":"49","author":"R Nakashima","year":"2009","unstructured":"Nakashima, R. et al. The RIG-I-like receptor IFIH1\/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology 49, 433\u2013440 (2009).","journal-title":"Rheumatology"},{"key":"1188_CR37","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1093\/rheumatology\/ker518","volume":"51","author":"T Koga","year":"2012","unstructured":"Koga, T. et al. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology 51, 1278\u20131284 (2012).","journal-title":"Rheumatology"},{"key":"1188_CR38","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000021943","volume":"99","author":"Y Ishikawa","year":"2020","unstructured":"Ishikawa, Y., Kasuya, T., Fujiwara, M. & Kita, Y. Tofacitinib for recurrence of antimelanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis after remission: a case report. Medicine 99, e21943 (2020).","journal-title":"Medicine"},{"key":"1188_CR39","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011024","volume":"97","author":"Y Endo","year":"2018","unstructured":"Endo, Y. et al. Recurrence of anti-MDA5 antibody-positive clinically amyopathic dermatomyositis after long-term remission. Medicine 97, e11024 (2018).","journal-title":"Medicine"},{"key":"1188_CR40","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3899\/jrheum.220139","volume":"50","author":"C Lv","year":"2023","unstructured":"Lv, C. et al. Coexistence of anti-Ro52 antibodies in anti-MDA5 antibody-positive dermatomyositis is highly associated with rapidly progressive interstitial lung disease and mortality risk. J. Rheumatol. 50, 219\u2013226 (2023).","journal-title":"J. Rheumatol."},{"key":"1188_CR41","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1093\/rheumatology\/keaa786","volume":"60","author":"A Xu","year":"2021","unstructured":"Xu, A. et al. Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease. Rheumatology 60, 3343\u20133351 (2021).","journal-title":"Rheumatology"},{"key":"1188_CR42","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1212\/WNL.0000000000009727","volume":"95","author":"Y Allenbach","year":"2020","unstructured":"Allenbach, Y. et al. Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: study of 121 cases. Neurology 95, e70\u2013e78 (2020).","journal-title":"Neurology"},{"key":"1188_CR43","doi-asserted-by":"publisher","first-page":"105136","DOI":"10.1016\/j.ebiom.2024.105136","volume":"104","author":"P David","year":"2024","unstructured":"David, P. et al. MDA5-autoimmunity and interstitial pneumonitis contemporaneous with the COVID-19 pandemic (MIP-C). EBioMedicine 104, 105136 (2024).","journal-title":"EBioMedicine"},{"key":"1188_CR44","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/s41590-021-00942-0","volume":"22","author":"T Yamada","year":"2021","unstructured":"Yamada, T. et al. RIG-I triggers a signaling-abortive anti-SARS-CoV-2 defense in human lung cells. Nat. Immunol. 22, 820\u2013828 (2021).","journal-title":"Nat. Immunol."},{"key":"1188_CR45","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s10067-015-2866-5","volume":"34","author":"J Zou","year":"2015","unstructured":"Zou, J., Guo, Q., Chi, J., Wu, H. & Bao, C. HRCT score and serum ferritin level are factors associated to the 1-year mortality of acute interstitial lung disease in clinically amyopathic dermatomyositis patients. Clin. Rheumatol. 34, 707\u2013714 (2015).","journal-title":"Clin. Rheumatol."},{"key":"1188_CR46","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1093\/rheumatology\/kes102","volume":"51","author":"T Gono","year":"2012","unstructured":"Gono, T. et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology 51, 1563\u20131570 (2012).","journal-title":"Rheumatology"},{"key":"1188_CR47","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1080\/14397595.2018.1548918","volume":"29","author":"A Nishioka","year":"2019","unstructured":"Nishioka, A. et al. Serum neopterin as well as ferritin, soluble interleukin-2 receptor, KL-6 and anti-MDA5 antibody titer provide markers of the response to therapy in patients with interstitial lung disease complicating anti-MDA5 antibody-positive dermatomyositis. Mod. Rheumatol. 29, 814\u2013820 (2019).","journal-title":"Mod. Rheumatol."},{"key":"1188_CR48","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s12890-022-02106-8","volume":"22","author":"T Liu","year":"2022","unstructured":"Liu, T. et al. Neutrophil-to-lymphocyte ratio is a predictive marker for anti-MDA5 positive dermatomyositis. BMC Pulm. Med. 22, 316 (2022).","journal-title":"BMC Pulm. Med."},{"key":"1188_CR49","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1186\/s12890-023-02706-y","volume":"23","author":"FP Ren","year":"2023","unstructured":"Ren, F. P. et al. Characteristics and prognostic implications of peripheral blood lymphocyte subsets in patients with anti-MDA5 antibody positive dermatomyositis-interstitial lung disease. BMC Pulm. Med. 23, 411 (2023).","journal-title":"BMC Pulm. Med."},{"key":"1188_CR50","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1007\/s10067-023-06624-6","volume":"42","author":"P Zhang","year":"2023","unstructured":"Zhang, P. et al. Plasma proteomic profiling reveals KRT19 could be a potential biomarker in patients with anti-MDA5+ dermatomyositis. Clin. Rheumatol. 42, 2145\u20132154 (2023).","journal-title":"Clin. Rheumatol."},{"key":"1188_CR51","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1093\/rheumatology\/kead117","volume":"62","author":"Y Liu","year":"2023","unstructured":"Liu, Y. et al. IFN-beta and EIF2AK2 are potential biomarkers for interstitial lung disease in anti-MDA5 positive dermatomyositis. Rheumatology 62, 3724\u20133731 (2023).","journal-title":"Rheumatology"},{"key":"1188_CR52","first-page":"5960","volume":"16","author":"Y Liu","year":"2018","unstructured":"Liu, Y. et al. Characteristics and predictors of malignancy in dermatomyositis: analysis of 239 patients from northern China. Oncol. Lett. 16, 5960\u20135968 (2018).","journal-title":"Oncol. Lett."},{"key":"1188_CR53","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/rheumatology\/kel161","volume":"46","author":"K Kaji","year":"2007","unstructured":"Kaji, K. et al. Identification of a novel autoantibody reactive with 155 and 140\u2009kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology 46, 25\u201328 (2007).","journal-title":"Rheumatology"},{"key":"1188_CR54","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1093\/rheumatology\/kem359","volume":"47","author":"H Gunawardena","year":"2008","unstructured":"Gunawardena, H. et al. Clinical associations of autoantibodies to a p155\/140\u2009kDa doublet protein in juvenile dermatomyositis. Rheumatology 47, 324\u2013328 (2008).","journal-title":"Rheumatology"},{"key":"1188_CR55","doi-asserted-by":"publisher","first-page":"R79","DOI":"10.1186\/ar3802","volume":"14","author":"M Satoh","year":"2012","unstructured":"Satoh, M. et al. Autoantibodies to transcription intermediary factor (TIF)1\u03b2 associated with dermatomyositis. Arthritis Res. Ther. 14, R79 (2012).","journal-title":"Arthritis Res. Ther."},{"key":"1188_CR56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0154746","volume":"11","author":"N Mugii","year":"2016","unstructured":"Mugii, N. et al. Oropharyngeal dysphagia in dermatomyositis: associations with clinical and laboratory features including autoantibodies. PLoS ONE 11, e0154746 (2016).","journal-title":"PLoS ONE"},{"key":"1188_CR57","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/joim.12444","volume":"280","author":"LG Rider","year":"2016","unstructured":"Rider, L. G. & Nistala, K. The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes. J. Intern. Med. 280, 24\u201338 (2016).","journal-title":"J. Intern. Med."},{"key":"1188_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2478\/rir-2022-0001","volume":"3","author":"F Halilu","year":"2022","unstructured":"Halilu, F. & Christopher-Stine, L. Myositis-specific antibodies: overview and clinical utilization. Rheumatol. Immunol. Res. 3, 1\u201310 (2022).","journal-title":"Rheumatol. Immunol. Res."},{"key":"1188_CR59","doi-asserted-by":"publisher","first-page":"102533","DOI":"10.1016\/j.autrev.2020.102533","volume":"19","author":"MP Chung","year":"2020","unstructured":"Chung, M. P. et al. Calcinosis biomarkers in adult and juvenile dermatomyositis. Autoimmun. Rev. 19, 102533 (2020).","journal-title":"Autoimmun. Rev."},{"key":"1188_CR60","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1001\/jamadermatol.2013.10416","volume":"150","author":"A Valenzuela","year":"2014","unstructured":"Valenzuela, A., Chung, L., Casciola-Rosen, L. & Fiorentino, D. Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis. JAMA Dermatol. 150, 724\u2013729 (2014).","journal-title":"JAMA Dermatol."},{"key":"1188_CR61","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.jaad.2014.12.009","volume":"72","author":"DF Fiorentino","year":"2015","unstructured":"Fiorentino, D. F. et al. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1\u03b3 antibodies in adults with dermatomyositis. J. Am. Acad. Dermatol. 72, 449\u2013455 (2015).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1188_CR62","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1136\/ard.2006.068502","volume":"66","author":"H Chinoy","year":"2007","unstructured":"Chinoy, H., Fertig, N., Oddis, C. V., Ollier, W. E. R. & Cooper, R. G. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann. Rheum. Dis. 66, 1345\u20131349 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"1188_CR63","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1002\/art.33379","volume":"64","author":"E Trallero-Aragu\u00e1s","year":"2012","unstructured":"Trallero-Aragu\u00e1s, E. et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 64, 523\u2013532 (2012).","journal-title":"Arthritis Rheum."},{"key":"1188_CR64","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1093\/rheumatology\/keac577","volume":"62","author":"N Cordel","year":"2023","unstructured":"Cordel, N. et al. Anti-transcription intermediary factor 1-gamma IgG2 isotype is associated with cancer in adult dermatomyositis: an ENMC multinational study. Rheumatology 62, 1711\u20131715 (2023).","journal-title":"Rheumatology"},{"key":"1188_CR65","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1093\/rheumatology\/keq153","volume":"49","author":"K Hoshino","year":"2010","unstructured":"Hoshino, K. et al. Anti-MDA5 and anti-TIF1-\u03b3 antibodies have clinical significance for patients with dermatomyositis. Rheumatology 49, 1726\u20131733 (2010).","journal-title":"Rheumatology"},{"key":"1188_CR66","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1093\/rheumatology\/kez572","volume":"59","author":"J De Vooght","year":"2020","unstructured":"De Vooght, J. et al. Anti-TIF1-\u03b3autoantibodies: warning lights of a tumour autoantigen. Rheumatology 59, 469\u2013477 (2020).","journal-title":"Rheumatology"},{"key":"1188_CR67","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/25785826.2020.1791402","volume":"44","author":"Y Kotobuki","year":"2020","unstructured":"Kotobuki, Y., Tonomura, K. & Fujimoto, M. Transcriptional intermediary factor 1 (TIF1) and anti-TIF1\u03b3 antibody-positive dermatomyositis. Immunol. Med. 44, 23\u201329 (2020).","journal-title":"Immunol. Med."},{"key":"1188_CR68","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1093\/rheumatology\/kex413","volume":"57","author":"I Pinal-Fernandez","year":"2018","unstructured":"Pinal-Fernandez, I. et al. Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis. Rheumatology 57, 388\u2013396 (2018).","journal-title":"Rheumatology"},{"key":"1188_CR69","doi-asserted-by":"publisher","first-page":"e281","DOI":"10.1093\/rheumatology\/keae182","volume":"63","author":"HD Nguyen","year":"2024","unstructured":"Nguyen, H. D. et al. TIF1-gamma IgG2 isotype is not associated with malignancy in juvenile dermatomyositis patients. Rheumatology 63, e281\u2013e284 (2024).","journal-title":"Rheumatology"},{"key":"1188_CR70","first-page":"75","volume":"25","author":"BL Adler","year":"2018","unstructured":"Adler, B. L. & Christopher-Stine, L. Triggers of inflammatory myopathy: insights into pathogenesis. Discov. Med. 25, 75\u201383 (2018).","journal-title":"Discov. Med."},{"key":"1188_CR71","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1136\/annrheumdis-2019-215046","volume":"78","author":"S Rothwell","year":"2019","unstructured":"Rothwell, S. et al. Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups. Ann. Rheum. Dis. 78, 996\u20131002 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"1188_CR72","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/s41584-023-01045-w","volume":"19","author":"AGS Oldroyd","year":"2023","unstructured":"Oldroyd, A. G. S. et al. International guideline for idiopathic inflammatory myopathy-associated cancer screening: an international myositis assessment and clinical studies group (IMACS) initiative. Nat. Rev. Rheumatol. 19, 805\u2013817 (2023).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1188_CR73","first-page":"S787","volume":"56","author":"IN Targoff","year":"2007","unstructured":"Targoff, I. N., Trieu, E. P., Levy-Nato, M., Fertig, N. & Oddis, C. V. Sera with autoantibodies to the MJ antigen react with NXP2. Arthritis Rheum. 56, S787 (2007).","journal-title":"Arthritis Rheum."},{"key":"1188_CR74","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1242\/jcs.063586","volume":"123","author":"Y Mimura","year":"2010","unstructured":"Mimura, Y., Takahashi, K., Kawata, K., Akazawa, T. & Inoue, N. Two-step colocalization of MORC3 with PML nuclear bodies. J. Cell Sci. 123, 2014\u20132024 (2010).","journal-title":"J. Cell Sci."},{"key":"1188_CR75","first-page":"S139","volume":"40","author":"CV Oddis","year":"1997","unstructured":"Oddis, C. V. Clinical and serological characterization of the anti-MJ antibody in childhood myositis. Arthritis Rheum. 40, S139 (1997).","journal-title":"Arthritis Rheum."},{"key":"1188_CR76","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1093\/rheumatology\/keab518","volume":"61","author":"Y Ichimura","year":"2022","unstructured":"Ichimura, Y. et al. Anti-nuclear matrix protein 2 antibody-positive inflammatory myopathies represent extensive myositis without dermatomyositis-specific rash. Rheumatology 61, 1222\u20131227 (2022).","journal-title":"Rheumatology"},{"key":"1188_CR77","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1093\/rheumatology\/keu259","volume":"53","author":"SL Tansley","year":"2014","unstructured":"Tansley, S. L. et al. Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset. Rheumatology 53, 2204\u20132208 (2014).","journal-title":"Rheumatology"},{"key":"1188_CR78","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1002\/acr.23188","volume":"69","author":"J Albayda","year":"2017","unstructured":"Albayda, J. et al. Antinuclear matrix protein 2 autoantibodies and edema, muscle disease, and malignancy risk in dermatomyositis patients. Arthritis Care Res. 69, 1771\u20131776 (2017).","journal-title":"Arthritis Care Res."},{"key":"1188_CR79","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","volume":"7","author":"IE Lundberg","year":"2021","unstructured":"Lundberg, I. E. et al. Idiopathic inflammatory myopathies. Nat. Rev. Dis. Prim. 7, 86 (2021).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1188_CR80","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12969-020-00486-x","volume":"19","author":"Y Xu","year":"2021","unstructured":"Xu, Y. et al. Gastrointestinal perforation in anti-NXP2 antibody-associated juvenile dermatomyositis: case reports and a review of the literature. Pediatr. Rheumatol. Online J. 19, 2 (2021).","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"1188_CR81","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003901","volume":"10","author":"Y Fu","year":"2024","unstructured":"Fu, Y. et al. Severe gastrointestinal involvements in patients with adult dermatomyositis with anti-NXP2 antibody. RMD Open\u00a010, e003901 (2024).","journal-title":"RMD Open"},{"key":"1188_CR82","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1111\/1756-185X.14755","volume":"26","author":"N Uchio","year":"2023","unstructured":"Uchio, N. et al. Anti-nuclear matrix protein 2 antibody-positive dermatomyositis with gastrointestinal ulcers: a case report. Int. J. Rheum. Dis. 26, 2572\u20132575 (2023).","journal-title":"Int. J. Rheum. Dis."},{"key":"1188_CR83","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12969-020-00492-z","volume":"19","author":"X Wang","year":"2021","unstructured":"Wang, X. et al. Clinical characteristics and poor predictors of anti-NXP2 antibody-associated Chinese JDM children. Pediatr. Rheumatol. Online J. 19, 6 (2021).","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"1188_CR84","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1136\/annrheumdis-2011-200697","volume":"71","author":"Y Ichimura","year":"2012","unstructured":"Ichimura, Y. et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann. Rheum. Dis. 71, 710\u2013713 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"1188_CR85","doi-asserted-by":"publisher","first-page":"S153","DOI":"10.1016\/j.nmd.2017.06.218","volume":"27","author":"O Landon-Cardinal","year":"2017","unstructured":"Landon-Cardinal, O. et al. Anti-Mi2 dermatomyositis revisited: pure DM phenotype with muscle fiber necrosis and high risk of malignancy. Neuromuscul. Disord. 27, S153 (2017).","journal-title":"Neuromuscul. Disord."},{"key":"1188_CR86","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s11926-018-0733-5","volume":"20","author":"PW Wolstencroft","year":"2018","unstructured":"Wolstencroft, P. W. & Fiorentino, D. F. Dermatomyositis clinical and pathological phenotypes associated with myositis-specific autoantibodies. Curr. Rheumatol. Rep. 20, 28 (2018).","journal-title":"Curr. Rheumatol. Rep."},{"key":"1188_CR87","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/nan.12528","volume":"45","author":"SA Yasin","year":"2019","unstructured":"Yasin, S. A. et al. Histological heterogeneity in a large clinical cohort of juvenile idiopathic inflammatory myopathy: analysis by myositis autoantibody and pathological features. Neuropathol. Appl. Neurobiol. 45, 495\u2013512 (2019).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"1188_CR88","doi-asserted-by":"publisher","first-page":"e1768","DOI":"10.1212\/WNL.0000000000008443","volume":"93","author":"I Pinal-Fernandez","year":"2019","unstructured":"Pinal-Fernandez, I. et al. More prominent muscle involvement in patients with dermatomyositis with anti-Mi2 autoantibodies. Neurology 93, e1768\u2013e1777 (2019).","journal-title":"Neurology"},{"key":"1188_CR89","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1093\/rheumatology\/keaa739","volume":"60","author":"M Fornaro","year":"2021","unstructured":"Fornaro, M. et al. Severe muscle damage with myofiber necrosis and macrophage infiltrates characterize anti-Mi2 positive dermatomyositis. Rheumatology 60, 2916\u20132926 (2021).","journal-title":"Rheumatology"},{"key":"1188_CR90","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1684\/ejd.2020.3750","volume":"30","author":"L Liang","year":"2020","unstructured":"Liang, L. et al. Anti-Mi-2 antibodies characterize a distinct clinical subset of dermatomyositis with favourable prognosis. Eur. J. Dermatol. 30, 151\u2013158 (2020).","journal-title":"Eur. J. Dermatol."},{"key":"1188_CR91","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1136\/annrheumdis-2012-201736","volume":"72","author":"M Fujimoto","year":"2013","unstructured":"Fujimoto, M. et al. Autoantibodies to small ubiquitin-like modifier activating enzymes in Japanese patients with dermatomyositis: comparison with a UK Caucasian cohort. Ann. Rheum. Dis. 72, 151\u2013153 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"1188_CR92","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1111\/1756-185X.13593","volume":"22","author":"T Gono","year":"2019","unstructured":"Gono, T. et al. Two cases with autoantibodies to small ubiquitin-like modifier activating enzyme: a potential unique subset of dermatomyositis-associated interstitial lung disease. Int. J. Rheum. Dis. 22, 1582\u20131586 (2019).","journal-title":"Int. J. Rheum. Dis."},{"key":"1188_CR93","doi-asserted-by":"publisher","first-page":"3932","DOI":"10.1093\/rheumatology\/kead154","volume":"62","author":"J Demortier","year":"2023","unstructured":"Demortier, J. et al. Anti-SAE autoantibody in dermatomyositis: original comparative study and review of the literature. Rheumatology 62, 3932\u20133939 (2023).","journal-title":"Rheumatology"},{"key":"1188_CR94","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/acr2.11247","volume":"3","author":"J Albayda","year":"2021","unstructured":"Albayda, J. et al. A North American cohort of anti-SAE dermatomyositis: clinical phenotype, testing, and review of cases. ACR Open Rheumatol. 3, 287\u2013294 (2021).","journal-title":"ACR Open Rheumatol."},{"key":"1188_CR95","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-00240-6","volume":"7","author":"Y Ge","year":"2017","unstructured":"Ge, Y., Lu, X., Shu, X., Peng, Q. & Wang, G. Clinical characteristics of anti-SAE antibodies in Chinese patients with dermatomyositis in comparison with different patient cohorts. Sci. Rep. 7, 188 (2017).","journal-title":"Sci. Rep."},{"key":"1188_CR96","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1136\/ard.2008.097162","volume":"68","author":"ZE Betteridge","year":"2009","unstructured":"Betteridge, Z. E. et al. Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis. Ann. Rheum. Dis. 68, 1621\u20131625 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"1188_CR97","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1093\/rheumatology\/keaa034","volume":"59","author":"Y Zuo","year":"2020","unstructured":"Zuo, Y. et al. Clinical significance of radiological patterns of HRCT and their association with macrophage activation in dermatomyositis. Rheumatology 59, 2829\u20132837 (2020).","journal-title":"Rheumatology"},{"key":"1188_CR98","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/s13075-017-1469-8","volume":"19","author":"H Yang","year":"2017","unstructured":"Yang, H. et al. Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study. Arthritis Res. Ther. 19, 259 (2017).","journal-title":"Arthritis Res. Ther."},{"key":"1188_CR99","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11926-018-0732-6","volume":"20","author":"I Pinal-Fernandez","year":"2018","unstructured":"Pinal-Fernandez, I., Casal-Dominguez, M. & Mammen, A. L. Immune-mediated necrotizing myopathy. Curr. Rheumatol. Rep. 20, 21 (2018).","journal-title":"Curr. Rheumatol. Rep."},{"key":"1188_CR100","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.nmd.2014.01.002","volume":"24","author":"L Wang","year":"2014","unstructured":"Wang, L. et al. Myopathy with anti-signal recognition particle antibodies: clinical and histopathological features in Chinese patients. Neuromuscul. Disord. 24, 335\u2013341 (2014).","journal-title":"Neuromuscul. Disord."},{"key":"1188_CR101","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1093\/rheumatology\/kew503","volume":"56","author":"J Svensson","year":"2017","unstructured":"Svensson, J., Arkema, E. V., Lundberg, I. E. & Holmqvist, M. Incidence and prevalence of idiopathic inflammatory myopathies in Sweden: a nationwide population-based study. Rheumatology 56, 802\u2013810 (2017).","journal-title":"Rheumatology"},{"key":"1188_CR102","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1136\/annrheumdis-2013-205127","volume":"74","author":"C Dobloug","year":"2015","unstructured":"Dobloug, C. et al. Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort. Ann. Rheum. Dis. 74, 1551\u20131556 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"1188_CR103","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.2169\/internalmedicine.0303-17","volume":"57","author":"T Kusumoto","year":"2018","unstructured":"Kusumoto, T. et al. Development of necrotizing myopathy following interstitial lung disease with anti-signal recognition particle antibody. Intern. Med. 57, 2045\u20132049 (2018).","journal-title":"Intern. Med."},{"key":"1188_CR104","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12890-021-01802-1","volume":"22","author":"Y Ge","year":"2022","unstructured":"Ge, Y. et al. Interstitial lung disease is not rare in immune-mediated necrotizing myopathy with anti-signal recognition particle antibodies. BMC Pulm. Med. 22, 14 (2022).","journal-title":"BMC Pulm. Med."},{"key":"1188_CR105","doi-asserted-by":"publisher","first-page":"1146817","DOI":"10.3389\/fimmu.2023.1146817","volume":"14","author":"M Bandeira","year":"2023","unstructured":"Bandeira, M. et al. Predictors of cardiac involvement in idiopathic inflammatory myopathies. Front. Immunol. 14, 1146817 (2023).","journal-title":"Front. Immunol."},{"key":"1188_CR106","doi-asserted-by":"publisher","first-page":"1019972","DOI":"10.3389\/fimmu.2022.1019972","volume":"13","author":"X Ma","year":"2022","unstructured":"Ma, X. & Bu, B. T. Anti-SRP immune-mediated necrotizing myopathy: a critical review of current concepts. Front. Immunol. 13, 1019972 (2022).","journal-title":"Front. Immunol."},{"key":"1188_CR107","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","volume":"28","author":"Y Allenbach","year":"2018","unstructured":"Allenbach, Y. et al. 224th ENMC International workshop: clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14\u201316 October 2016. Neuromuscul. Disord. 28, 87\u201399 (2018).","journal-title":"Neuromuscul. Disord."},{"key":"1188_CR108","first-page":"927","volume":"35","author":"KA Rouster-Stevens","year":"2008","unstructured":"Rouster-Stevens, K. A. & Pachman, L. M. Autoantibody to signal recognition particle in African American girls with juvenile polymyositis. J. Rheumatol. 35, 927\u2013929 (2008).","journal-title":"J. Rheumatol."},{"key":"1188_CR109","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12969-017-0205-x","volume":"15","author":"EL Binns","year":"2017","unstructured":"Binns, E. L. et al. Effective induction therapy for anti-SRP associated myositis in childhood: a small case series and review of the literature. Pediatr. Rheumatol. Online J. 15, 77 (2017).","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"1188_CR110","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/acr.22920","volume":"69","author":"I Pinal-Fernandez","year":"2017","unstructured":"Pinal-Fernandez, I. et al. Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle. Arthritis Care Res. 69, 263\u2013270 (2017).","journal-title":"Arthritis Care Res."},{"key":"1188_CR111","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1097\/BOR.0000000000000832","volume":"33","author":"T Kurashige","year":"2021","unstructured":"Kurashige, T. Anti-HMGCR myopathy: clinical and histopathological features, and prognosis. Curr. Opin. Rheumatol. 33, 554\u2013562 (2021).","journal-title":"Curr. Opin. Rheumatol."},{"key":"1188_CR112","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1080\/1744666X.2018.1440206","volume":"14","author":"A Selva-O\u2019Callaghan","year":"2018","unstructured":"Selva-O\u2019Callaghan, A. et al. Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations. Expert. Rev. Clin. Immunol. 14, 215\u2013224 (2018).","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"1188_CR113","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/acr.23113","volume":"69","author":"T Kishi","year":"2017","unstructured":"Kishi, T. et al. Association of anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase autoantibodies with DRB1*07:01 and severe myositis in juvenile myositis patients. Arthritis Care Res. 69, 1088\u20131094 (2017).","journal-title":"Arthritis Care Res."},{"key":"1188_CR114","doi-asserted-by":"publisher","first-page":"103468","DOI":"10.1016\/j.autrev.2023.103468","volume":"22","author":"T Khoo","year":"2023","unstructured":"Khoo, T. & Chinoy, H. Anti-HMGCR immune-mediated necrotising myopathy: addressing the remaining issues. Autoimmun. Rev. 22, 103468 (2023).","journal-title":"Autoimmun. Rev."},{"key":"1188_CR115","first-page":"787","volume":"56","author":"E Tiniakou","year":"2017","unstructured":"Tiniakou, E. et al. More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutarylcoenzyme A reductase-associated autoimmune myopathy. Rheumatology 56, 787\u2013794 (2017).","journal-title":"Rheumatology"},{"key":"1188_CR116","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1093\/brain\/aww054","volume":"139","author":"Y Allenbach","year":"2016","unstructured":"Allenbach, Y. et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain 139, 2131\u20132135 (2016).","journal-title":"Brain"},{"key":"1188_CR117","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1378\/chest.10-0180","volume":"138","author":"GR Connors","year":"2010","unstructured":"Connors, G. R., Christopher-Stine, L., Oddis, C. V. & Danoff, S. K. Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years? Chest 138, 1464\u20131474 (2010).","journal-title":"Chest"},{"key":"1188_CR118","doi-asserted-by":"publisher","first-page":"103204","DOI":"10.1016\/j.autrev.2022.103204","volume":"21","author":"Y Muro","year":"2022","unstructured":"Muro, Y. et al. Two novel anti-aminoacyl tRNA synthetase antibodies: autoantibodies against cysteinyl-tRNA synthetase and valyl-tRNA synthetase. Autoimmun. Rev. 21, 103204 (2022).","journal-title":"Autoimmun. Rev."},{"key":"1188_CR119","doi-asserted-by":"publisher","first-page":"102951","DOI":"10.1016\/j.jaut.2022.102951","volume":"134","author":"C Preger","year":"2023","unstructured":"Preger, C. et al. Autoantigenic properties of the aminoacyl tRNA synthetase family in idiopathic inflammatory myopathies. J. Autoimmun. 134, 102951 (2023).","journal-title":"J. Autoimmun."},{"key":"1188_CR120","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1136\/ard-2022-222686","volume":"82","author":"JB Vulsteke","year":"2023","unstructured":"Vulsteke, J. B. et al. Mass spectrometry-based identification of new anti-Ly and known antisynthetase autoantibodies. Ann. Rheum. Dis. 82, 546\u2013555 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"1188_CR121","doi-asserted-by":"publisher","first-page":"4453","DOI":"10.3390\/ijms25084453","volume":"21","author":"P Patel","year":"2024","unstructured":"Patel, P., Marinock, J. M., Ajmeri, A. & Brent, L. H. A review of antisynthetase syndrome-associated interstitial lung disease. Int. J. Mol. Sci. 21, 4453 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"1188_CR122","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12016-015-8510-y","volume":"52","author":"M Satoh","year":"2017","unstructured":"Satoh, M., Tanaka, S., Ceribelli, A., Calise, S. J. & Chan, E. K. L. A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy. Clin. Rev. Allergy Immunol. 52, 1\u201319 (2017).","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"1188_CR123","doi-asserted-by":"publisher","first-page":"101767","DOI":"10.1016\/j.berh.2022.101767","volume":"36","author":"AS Galindo-Feria","year":"2022","unstructured":"Galindo-Feria, A. S., Wang, G. & Lundberg, I. E. Autoantibodies: pathogenic or epiphenomenon. Best. Pract. Res. Clin. Rheumatol. 36, 101767 (2022).","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"1188_CR124","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.autrev.2012.01.006","volume":"11","author":"I Marie","year":"2012","unstructured":"Marie, I. et al. Comparison of long-term outcome between anti-Jo1- and anti-PL7\/PL12 positive patients with antisynthetase syndrome. Autoimmun. Rev. 11, 739\u2013745 (2012).","journal-title":"Autoimmun. Rev."},{"key":"1188_CR125","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.ejim.2013.01.002","volume":"24","author":"I Marie","year":"2013","unstructured":"Marie, I. et al. Clinical manifestations and outcome of anti-PL7 positive patients with antisynthetase syndrome. Eur. J. Intern. Med. 24, 474\u2013479 (2013).","journal-title":"Eur. J. Intern. Med."},{"key":"1188_CR126","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.autrev.2019.05.002","volume":"18","author":"JB Vulsteke","year":"2019","unstructured":"Vulsteke, J. B. et al. Anti-OJ autoantibodies: rare or underdetected? Autoimmun. Rev. 18, 658\u2013664 (2019).","journal-title":"Autoimmun. Rev."},{"key":"1188_CR127","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060442","volume":"8","author":"Y Hamaguchi","year":"2013","unstructured":"Hamaguchi, Y. et al. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS ONE 8, e60442 (2013).","journal-title":"PLoS ONE"},{"key":"1188_CR128","doi-asserted-by":"publisher","first-page":"275","DOI":"10.5152\/eurjrheum.2018.17167","volume":"5","author":"A Kapoor","year":"2018","unstructured":"Kapoor, A., Vaidyan, P., Jalil, B. & Upaluri, C. Novel case of anti-synthetase syndrome. Eur. J. Rheumatol. 5, 275\u2013277 (2018).","journal-title":"Eur. J. Rheumatol."},{"key":"1188_CR129","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1001\/jamaneurol.2017.0934","volume":"74","author":"E Noguchi","year":"2017","unstructured":"Noguchi, E. et al. Skeletal muscle involvement in antisynthetase syndrome. JAMA Neurol. 74, 992\u2013999 (2017).","journal-title":"JAMA Neurol."},{"key":"1188_CR130","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1136\/ard-2023-225284","volume":"83","author":"S Wu","year":"2024","unstructured":"Wu, S. et al. Novel endotypes of antisynthetase syndrome identified independent of anti-aminoacyl transfer RNA synthetase antibody specificity that improve prognostic stratification. Ann. Rheum. Dis. 83, 775\u2013786 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1188_CR131","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s10067-014-2730-z","volume":"33","author":"LA Aguila","year":"2014","unstructured":"Aguila, L. A. et al. Clinical and laboratory features of overlap syndromes of idiopathic inflammatory myopathies associated with systemic lupus erythematosus, systemic sclerosis, or rheumatoid arthritis. Clin. Rheumatol. 33, 1093\u20131098 (2014).","journal-title":"Clin. Rheumatol."},{"key":"1188_CR132","doi-asserted-by":"crossref","unstructured":"Louis Gaspar, B. in Current Trends and Future Prospects Immune-Mediated Myopathies and Neuropathies 101\u2013102 (Springer, 2023).","DOI":"10.1007\/978-981-19-8421-1_6"},{"key":"1188_CR133","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00296-021-05075-z","volume":"42","author":"D Srikantharajah","year":"2022","unstructured":"Srikantharajah, D., Lloyd, M. E. & Kiely, P. D. W. Rituximab and intravenous immunoglobulin treatment in PM\/Scl antibody-associated disease: case-based review. Rheumatol. Int. 42, 359\u2013364 (2022).","journal-title":"Rheumatol. Int."},{"key":"1188_CR134","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1016\/j.ekir.2019.07.002","volume":"4","author":"M Jacquier","year":"2019","unstructured":"Jacquier, M. et al. Scleroderma renal crisis in a systemic sclerosis with anti-PM\/Scl antibodies. Kidney Int. Rep. 4, 1499\u20131502 (2019).","journal-title":"Kidney Int. Rep."},{"key":"1188_CR135","doi-asserted-by":"publisher","first-page":"R22","DOI":"10.1186\/ar2614","volume":"11","author":"K Hanke","year":"2009","unstructured":"Hanke, K. et al. Antibodies against PM\/Scl-75 and PM\/Scl-100 are independent markers for different subsets of systemic sclerosis patients. Arthritis Res. Ther. 11, R22 (2009).","journal-title":"Arthritis Res. Ther."},{"key":"1188_CR136","doi-asserted-by":"publisher","first-page":"55","DOI":"10.4103\/idoj.idoj_188_22","volume":"14","author":"AK Babu","year":"2023","unstructured":"Babu, A. K., Mizaj, Z., Thomas, J. & Chacko, M. Clinical significance of myositis-specific and myositis-associated antibody profiles in dermatomyositis. Indian. Dermatol. Online J. 14, 55\u201360 (2023).","journal-title":"Indian. Dermatol. Online J."},{"key":"1188_CR137","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1007\/s10067-022-06115-0","volume":"41","author":"JG J\u00fanior","year":"2022","unstructured":"J\u00fanior, J. G., Mugii, N., Inaoka, P. T., Sampaio-Barros, P. D. & Shinjo, S. K. Inflammatory myopathies overlapping with systemic sclerosis: a systematic review. Clin. Rheumatol. 41, 1951\u20131963 (2022).","journal-title":"Clin. Rheumatol."},{"key":"1188_CR138","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.3899\/jrheum.151445","volume":"43","author":"L Fotis","year":"2016","unstructured":"Fotis, L., Baszis, K. W., White, A. J. & French, A. R. Four cases of anti-PM\/Scl antibody-positive juvenile overlap syndrome with features of myositis and systemic sclerosis. J. Rheumatol. 43, 1768\u20131769 (2016).","journal-title":"J. Rheumatol."},{"key":"1188_CR139","doi-asserted-by":"publisher","first-page":"367","DOI":"10.5114\/reum.2021.112350","volume":"59","author":"L Rutkowska-Sak","year":"2021","unstructured":"Rutkowska-Sak, L., Gietka, P., Gazda, A. & Kolodziejczyk, B. Juvenile systemic sclerosis \u2014 observations of one clinical centre. Reumatologia 59, 367\u2013372 (2021).","journal-title":"Reumatologia"},{"key":"1188_CR140","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/0002-9343(72)90064-2","volume":"52","author":"GC Sharp","year":"1972","unstructured":"Sharp, G. C., Irvin, W. S., Tan, E. M., Gould, R. G. & Holman, H. R. Mixed connective tissue disease\u2014an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am. J. Med. 52, 148\u2013159 (1972).","journal-title":"Am. J. Med."},{"key":"1188_CR141","first-page":"326","volume":"56","author":"NCO Ciang","year":"2017","unstructured":"Ciang, N. C. O., Pereira, N. & Isenberg, D. A. Mixed connective tissue disease\u2014enigma variations? Rheumatology 56, 326\u2013333 (2017).","journal-title":"Rheumatology"},{"key":"1188_CR142","doi-asserted-by":"publisher","first-page":"1759720","DOI":"10.1177\/1759720X231181336","volume":"15","author":"Y Ge","year":"2023","unstructured":"Ge, Y. et al. Clinical characteristics of myositis patients with isolated anti-U1 ribonucleoprotein antibody resemble immune-mediated necrotizing myopathy. Ther. Adv. Musculoskelet. Dis. 15, 1759720\u2013231181336 (2023).","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"1188_CR143","doi-asserted-by":"publisher","first-page":"e1416","DOI":"10.1212\/WNL.0000000000007188","volume":"92","author":"M Casal-Dominguez","year":"2019","unstructured":"Casal-Dominguez, M. et al. Muscular and extramuscular features of myositis patients with anti-U1-RNP autoantibodies. Neurology 92, e1416\u2013e1426 (2019).","journal-title":"Neurology"},{"key":"1188_CR144","first-page":"OD05","volume":"9","author":"S Lokesh","year":"2015","unstructured":"Lokesh, S., Tony, K., Raghupathy, Suresh, V. & Malepati, B. A rare case of mixed connective tissue disease (MCTD) with intricate features of lupus, polymyositis and rheumatoid arthritis presenting with severe myositis. J. Clin. Diagn. Res. 9, OD05\u2013OD07 (2015).","journal-title":"J. Clin. Diagn. Res."},{"key":"1188_CR145","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.15243","volume":"27","author":"S Guha","year":"2024","unstructured":"Guha, S. et al. Exploring clinical features and therapeutic outcomes in Indian children with mixed connective tissue disease: a multicenter study. Int. J. Rheum. Dis. 27, e15243 (2024).","journal-title":"Int. J. Rheum. Dis."},{"key":"1188_CR146","doi-asserted-by":"publisher","first-page":"102465","DOI":"10.1016\/j.autrev.2020.102465","volume":"19","author":"N Wesner","year":"2020","unstructured":"Wesner, N. et al. Anti-RNP antibodies delineate a subgroup of myositis: a systematic retrospective study on 46 patients. Autoimmun. Rev. 19, 102465 (2020).","journal-title":"Autoimmun. Rev."},{"key":"1188_CR147","doi-asserted-by":"publisher","first-page":"104804","DOI":"10.1016\/j.ebiom.2023.104804","volume":"96","author":"V Leclair","year":"2023","unstructured":"Leclair, V. et al. Distinct HLA associations with autoantibody-defined subgroups in idiopathic inflammatory myopathies. EBioMedicine 96, 104804 (2023).","journal-title":"EBioMedicine"},{"key":"1188_CR148","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.3390\/diagnostics13193080","volume":"13","author":"A Ghirardello","year":"2023","unstructured":"Ghirardello, A. et al. Detection of myositis autoantibodies by multi-analytic immunoassays in a large multicenter cohort of patients with definite idiopathic inflammatory myopathies. Diagnostics 13, 3080 (2023).","journal-title":"Diagnostics"},{"key":"1188_CR149","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1097\/RHU.0000000000002015","volume":"29","author":"E Pepper","year":"2023","unstructured":"Pepper, E., Vilar, L. & Ward, I. M. Clinical characteristics and prognostic value of Ro52\/SSA antibodies in idiopathic inflammatory myopathies. J. Clin. Rheumol. 29, 347\u2013353 (2023).","journal-title":"J. Clin. Rheumol."},{"key":"1188_CR150","doi-asserted-by":"publisher","first-page":"909","DOI":"10.6061\/clinics\/2013(07)04","volume":"68","author":"MG Pina Cruellas","year":"2013","unstructured":"Pina Cruellas, M. G. et al. Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis. Clinics 68, 909\u2013914 (2013).","journal-title":"Clinics"},{"key":"1188_CR151","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.3899\/jrheum.161480","volume":"44","author":"J Shi","year":"2017","unstructured":"Shi, J. et al. Clinical profiles and prognosis of patients with distinct antisynthetase autoantibodies. J. Rheumatol. 44, 1051\u20131057 (2017).","journal-title":"J. Rheumatol."},{"key":"1188_CR152","doi-asserted-by":"publisher","first-page":"ii10","DOI":"10.1093\/rap\/rkab054","volume":"5","author":"SK Sreevilasan","year":"2021","unstructured":"Sreevilasan, S. K., Devarasetti, P., Narahari, N. K., Desai, A. & Rajasekhar, L. Clinical profile and treatment outcomes in antisynthetase syndrome: a tertiary centre experience. Rheumatol. Adv. Pract. 5, ii10\u2013ii18 (2021). Suppl 2.","journal-title":"Rheumatol. Adv. Pract."},{"key":"1188_CR153","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s10067-007-0762-3","volume":"27","author":"VS Limaye","year":"2008","unstructured":"Limaye, V. S., Cassidy, J., Scott, G., Roberts-Thomson, P. J. & Gillis, D. Anti-Ro52 antibodies, antisynthetase antibodies, and antisynthetase syndrome. Clin. Rheumatol. 27, 521\u2013523 (2008).","journal-title":"Clin. Rheumatol."},{"key":"1188_CR154","doi-asserted-by":"publisher","first-page":"403","DOI":"10.3109\/14397595.2015.1091155","volume":"26","author":"Y Yamasaki","year":"2016","unstructured":"Yamasaki, Y. et al. Clinical subsets associated with different anti-aminoacyl transfer RNA synthetase antibodies and their association with coexisting anti-Ro52. Mod. Rheumatol. 26, 403\u2013409 (2016).","journal-title":"Mod. Rheumatol."},{"key":"1188_CR155","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.3899\/jrheum.150844","volume":"43","author":"J Bauhammer","year":"2016","unstructured":"Bauhammer, J. et al. Rituximab in the treatment of Jo1 antibody-associated antisynthetase syndrome: anti-Ro52 positivity as a marker for severity and treatment response. J. Rheumatol. 43, 1566\u20131574 (2016).","journal-title":"J. Rheumatol."},{"key":"1188_CR156","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1080\/08916930600623791","volume":"39","author":"R La Corte","year":"2006","unstructured":"La Corte, R., Lo Mo Naco, A., Locaputo, A., Dolzani, F. & Trotta, F. In patients with antisynthetase syndrome the occurrence of anti-Ro\/SSA antibodies causes a more severe interstitial lung disease. Autoimmunity 39, 249\u2013253 (2006).","journal-title":"Autoimmunity"},{"key":"1188_CR157","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1093\/rheumatology\/keab488","volume":"61","author":"C Shao","year":"2022","unstructured":"Shao, C. et al. Myositis specific antibodies are associated with isolated anti-Ro-52 associated interstitial lung disease. Rheumatology 61, 1083\u20131091 (2022).","journal-title":"Rheumatology"},{"key":"1188_CR158","doi-asserted-by":"publisher","first-page":"103013","DOI":"10.1016\/j.autrev.2021.103013","volume":"21","author":"P Decker","year":"2022","unstructured":"Decker, P. et al. An updated review of anti-Ro52 (TRIM21) antibodies impact in connective tissue diseases clinical management. Autoimmun. Rev. 21, 103013 (2022).","journal-title":"Autoimmun. Rev."},{"key":"1188_CR159","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1186\/s12887-021-02958-9","volume":"21","author":"J Xia","year":"2021","unstructured":"Xia, J. et al. Respiratory symptoms as initial manifestations of interstitial lung disease in clinically amyopathic juvenile dermatomyositis: a case report with literature review. BMC Pediatr. 21, 488 (2021).","journal-title":"BMC Pediatr."},{"key":"1188_CR160","doi-asserted-by":"publisher","first-page":"291","DOI":"10.21037\/atm-21-475","volume":"11","author":"Y Liu","year":"2023","unstructured":"Liu, Y., Zheng, Y., Hao, H. & Yuan, Y. Narrative review of autoantibodies in idiopathic inflammatory myopathies. Ann. Transl. Med. 11, 291 (2023).","journal-title":"Ann. Transl. Med."},{"key":"1188_CR161","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1007\/s00296-012-2412-6","volume":"33","author":"T Zenone","year":"2013","unstructured":"Zenone, T., Streichenberger, N. & Puget, M. Camptocormia as a clinical manifestation of polymyositis\/systemic sclerosis overlap myositis associated with anti-Ku. Rheumatol. Int. 33, 2411\u20132415 (2013).","journal-title":"Rheumatol. Int."},{"key":"1188_CR162","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1136\/annrheumdis-2018-214439","volume":"78","author":"L Spielmann","year":"2019","unstructured":"Spielmann, L. et al. Anti-Ku syndrome with elevated CK and anti-Ku syndrome with anti-dsDNA are two distinct entities with different outcomes. Ann. Rheum. Dis. 78, 1101\u20131106 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"1188_CR163","doi-asserted-by":"publisher","first-page":"e213","DOI":"10.1093\/rheumatology\/kead049","volume":"62","author":"M Sousa","year":"2023","unstructured":"Sousa, M. et al. Anti-Ku antibody syndrome: is it a distinct clinical entity? A cross-sectional study of 75 patients. Rheumatology 62, e213\u2013e215 (2023).","journal-title":"Rheumatology"},{"key":"1188_CR164","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.semarthrit.2021.04.012","volume":"51","author":"M Casal-Dominguez","year":"2021","unstructured":"Casal-Dominguez, M. et al. The phenotype of myositis patients with anti-Ku autoantibodies. Semin. Arthritis Rheum. 51, 728\u2013734 (2021).","journal-title":"Semin. Arthritis Rheum."},{"key":"1188_CR165","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.nmd.2024.05.008","volume":"40","author":"ED Batu","year":"2024","unstructured":"Batu, E. D. et al. Further expanding the phenotype of anti-Ku antibody associated disease in children and adolescents. Neuromuscul. Disord. 40, 7\u201315 (2024).","journal-title":"Neuromuscul. Disord."},{"key":"1188_CR166","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.1007\/s10067-023-06687-5","volume":"42","author":"S Kanda","year":"2023","unstructured":"Kanda, S. et al. Anti-Ku antibody-positive systemic sclerosis and idiopathic inflammatory myopathies overlap syndrome in children: a report of two cases and a review of the literature. Clin. Rheumatol. 42, 3411\u20133417 (2023).","journal-title":"Clin. Rheumatol."},{"key":"1188_CR167","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/ana.23840","volume":"73","author":"H Benjamin Larman","year":"2013","unstructured":"Benjamin Larman, H. et al. Cytosolic 5\u2032\u2010nucleotidase 1\u2009A autoimmunity in sporadic inclusion body myositis. Ann. Neurol. 73, 408\u2013418 (2013).","journal-title":"Ann. Neurol."},{"key":"1188_CR168","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/ana.23822","volume":"73","author":"H Pluk","year":"2013","unstructured":"Pluk, H. et al. Autoantibodies to cytosolic 5\u2032\u2010nucleotidase 1\u2009A in inclusion body myositis. Ann. Neurol. 73, 397\u2013407 (2013).","journal-title":"Ann. Neurol."},{"key":"1188_CR169","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.nmd.2024.03.001","volume":"37","author":"JB Lilleker","year":"2024","unstructured":"Lilleker, J. B. et al. 272nd ENMC international workshop: 10 years of progress \u2014 revision of the ENMC 2013 diagnostic criteria for inclusion body myositis and clinical trial readiness. 16\u201318 June 2023, Hoofddorp, The Netherlands.Neuromuscul. Disord. 37, 36\u201351 (2024).","journal-title":"Neuromuscul. Disord."},{"key":"1188_CR170","doi-asserted-by":"publisher","first-page":"322","DOI":"10.7861\/clinmedicine.17-4-322","volume":"17","author":"A Oldroyd","year":"2017","unstructured":"Oldroyd, A., Lilleker, J. & Chinoy, H. Idiopathic inflammatory myopathies \u2014 a guide to subtypes, diagnostic approach and treatment. Clin. Med. 17, 322\u2013328 (2017).","journal-title":"Clin. Med."},{"key":"1188_CR171","doi-asserted-by":"publisher","first-page":"384","DOI":"10.55563\/clinexprheumatol\/r625rm","volume":"40","author":"S Salam","year":"2022","unstructured":"Salam, S., Dimachkie, M. M., Hanna, M. G. & Machado, P. M. Diagnostic and prognostic value of anti-cN1A antibodies in inclusion body myositis. Clin. Exp. Rheumatol. 40, 384\u2013393 (2022).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1188_CR172","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1136\/annrheumdis-2017-212436","volume":"77","author":"RM Yeker","year":"2018","unstructured":"Yeker, R. M. et al. Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis. Ann. Rheum. Dis. 77, 714\u2013719 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"1188_CR173","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1002\/art.41660","volume":"73","author":"A Rietveld","year":"2021","unstructured":"Rietveld, A. et al. Anti\u2013cytosolic 5\u2032- nucleotidase 1\u2009A autoantibodies are absent in juvenile dermatomyositis. Arthritis Rheumatol. 73, 1329\u20131333 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"1188_CR174","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1002\/art.42059","volume":"74","author":"AL Mammen","year":"2022","unstructured":"Mammen, A. L., Pinal-Fernandez, I. & Rider, L. G. Conflicting reports of anti-cytosolic 5\u2032-nucleotidase 1\u2009A autoantibodies in juvenile dermatomyositis: comment on the article by Rietveld et al. Arthritis Rheumatol. 74, 911\u2013912 (2022).","journal-title":"Arthritis Rheumatol."},{"key":"1188_CR175","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1136\/annrheumdis-2014-206691","volume":"75","author":"MK Herbert","year":"2016","unstructured":"Herbert, M. K. et al. Disease specificity of autoantibodies to cytosolic 5\u2032-nucleotidase 1\u2009A in sporadic inclusion body myositis versus known autoimmune diseases. Ann. Rheum. Dis. 75, 696\u2013701 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"1188_CR176","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1002\/acr.22163","volume":"66","author":"K Kaji","year":"2014","unstructured":"Kaji, K. et al. Autoantibodies to RuvBL1 and RuvBL2: a novel systemic sclerosis-related antibody associated with diffuse cutaneous and skeletal muscle involvement. Arthritis Care Res. 66, 575\u2013584 (2014).","journal-title":"Arthritis Care Res."},{"key":"1188_CR177","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/antib12010013","volume":"12","author":"L Di Pietro","year":"2023","unstructured":"Di Pietro, L. et al. Anti-RuvBL1\/2 autoantibodies detection in a patient with overlap systemic sclerosis and polymyositis. Antibodies 12, 13 (2023).","journal-title":"Antibodies"},{"key":"1188_CR178","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001357","volume":"6","author":"O Landon-Cardinal","year":"2020","unstructured":"Landon-Cardinal, O. et al. Recognising the spectrum of scleromyositis: HEp-2 ANA patterns allow identification of a novel clinical subset with anti-SMN autoantibodies. RMD Open\u00a06, e001357 (2020).","journal-title":"RMD Open"},{"key":"1188_CR179","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003431","volume":"9","author":"H El Kamouni","year":"2023","unstructured":"El Kamouni, H. et al. Anti-SMN autoantibodies in mixed connective tissue disease are associated with a severe systemic sclerosis phenotype. RMD Open\u00a09, e003431 (2023).","journal-title":"RMD Open"},{"key":"1188_CR180","doi-asserted-by":"publisher","first-page":"4612","DOI":"10.1172\/JCI81031","volume":"125","author":"I Albrecht","year":"2015","unstructured":"Albrecht, I. et al. Development of autoantibodies against muscle-specific FHL1 in severe inflammatory myopathies. J. Clin. Invest. 125, 4612\u20134624 (2015).","journal-title":"J. Clin. Invest."},{"key":"1188_CR181","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1083\/jcb.200804077","volume":"183","author":"BS Cowling","year":"2008","unstructured":"Cowling, B. S. et al. Identification of FHL1 as a regulator of skeletal muscle mass: implications for human myopathy. J. Clin. Biol. 183, 1033\u20131048 (2008).","journal-title":"J. Clin. Biol."},{"key":"1188_CR182","doi-asserted-by":"publisher","first-page":"4145","DOI":"10.1093\/rheumatology\/keac003","volume":"61","author":"AS Galindo-Feria","year":"2022","unstructured":"Galindo-Feria, A. S. et al. Autoantibodies against four-and-a-half-LIM domain 1 (FHL1) in inflammatory myopathies: results from an Australian single-centre cohort. Rheumatology 61, 4145\u20134154 (2022).","journal-title":"Rheumatology"},{"key":"1188_CR183","doi-asserted-by":"publisher","first-page":"S1226","DOI":"10.1093\/rheumatology\/keac428","volume":"62","author":"MA Sherman","year":"2023","unstructured":"Sherman, M. A. et al. Anti-FHL1 autoantibodies in juvenile myositis are associated with anti-Ro52 autoantibodies but not with severe disease features. Rheumatology 62, S1226\u2013S1234 (2023).","journal-title":"Rheumatology"},{"key":"1188_CR184","doi-asserted-by":"publisher","DOI":"10.1172\/JCI150201","volume":"132","author":"DF Fiorentino","year":"2022","unstructured":"Fiorentino, D. F. et al. Immune responses to CCAR1 and other dermatomyositis autoantigens are associated with attenuated cancer emergence. J. Clin. Invest. 132, e150201 (2022).","journal-title":"J. Clin. Invest."},{"key":"1188_CR185","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1002\/art.42474","volume":"75","author":"D Fiorentino","year":"2023","unstructured":"Fiorentino, D. et al. Association of Anti-CCAR1 autoantibodies with decreased cancer risk relative to the general population in patients with anti-transcriptional intermediary factor 1\u03b3-positive dermatomyositis. Arthritis Rheumatol. 75, 1238\u20131245 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"1188_CR186","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1136\/ard-2022-222441","volume":"82","author":"Y Hosono","year":"2022","unstructured":"Hosono, Y. et al. Coexisting autoantibodies against transcription factor Sp4 are associated with decreased cancer risk in patients with dermatomyositis with anti-TIF1\u03b3autoantibodies. Ann. Rheum. Dis. 82, 246\u2013252 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"1188_CR187","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s40495-014-0012-8","volume":"1","author":"S Safe","year":"2015","unstructured":"Safe, S. MicroRNA-specificity protein (Sp) transcription factor interactions and significance in carcinogenesis. Curr. Pharmacol. Rep. 1, 73\u201378 (2015).","journal-title":"Curr. Pharmacol. Rep."},{"key":"1188_CR188","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1002\/art.42512","volume":"75","author":"MA Sherman","year":"2023","unstructured":"Sherman, M. A. et al. Autoantibodies recognizing specificity protein 4 co-occur with anti\u2013transcription intermediary factor 1 and are associated with distinct clinical features and immunogenetic risk factors in juvenile myositis. Arthritis Rheumatol. 75, 1668\u20131677 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"1188_CR189","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.autrev.2014.08.038","volume":"13","author":"M Labrador-Horrillo","year":"2014","unstructured":"Labrador-Horrillo, M. et al. Identification of a novel myositis-associated antibody directed against cortactin. Autoimmun. Rev. 13, 1008\u20131012 (2014).","journal-title":"Autoimmun. Rev."},{"key":"1188_CR190","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/art.41931","volume":"74","author":"I Pinal-Fernandez","year":"2021","unstructured":"Pinal-Fernandez, I. et al. Anti-cortactin autoantibodies are associated with key clinical features in adult myositis but are rarely present in juvenile myositis. Arthritis Rheumatol. 74, 358\u2013364 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"1188_CR191","first-page":"2007","volume":"263-273","author":"L Buday","year":"1775","unstructured":"Buday, L., & Downward, J. Roles of cortactin in tumor pathogenesis. Biochim. Biophys. Acta 263-273, 2007 (1775).","journal-title":"Biochim. Biophys. Acta"},{"key":"1188_CR192","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/BOR.0000000000000957","volume":"35","author":"MY Choi","year":"2023","unstructured":"Choi, M. Y., Satoh, M. & Fritzler, M. J. Update on autoantibodies and related biomarkers in autoimmune inflammatory myopathies. Curr. Opin. Rheumatol. 35, 383\u2013394 (2023).","journal-title":"Curr. Opin. Rheumatol."},{"key":"1188_CR193","doi-asserted-by":"publisher","first-page":"120391","DOI":"10.1016\/j.jns.2022.120391","volume":"442","author":"A Nagai","year":"2022","unstructured":"Nagai, A. et al. Clinical features of anti-mitochondrial M2 antibody-positive myositis: case series of 17 patients. J. Neurol. Sci. 442, 120391 (2022).","journal-title":"J. Neurol. Sci."},{"key":"1188_CR194","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1093\/brain\/aws106","volume":"135","author":"MH Maeda","year":"2012","unstructured":"Maeda, M. H., Tsuji, S. & Shimizu, J. Inflammatory myopathies associated with anti-mitochondrial antibodies. Brain 135, 1767\u20131777 (2012).","journal-title":"Brain"},{"key":"1188_CR195","first-page":"191","volume":"135","author":"GS Uhl","year":"1974","unstructured":"Uhl, G. S., Baldwin, J. L. & Arnett, F. C. Primary biliary cirrhosis in systemic sclerosis (scleroderma) and polymyositis. Johns. Hopkins Med. J. 135, 191\u2013198 (1974).","journal-title":"Johns. Hopkins Med. J."},{"key":"1188_CR196","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.2169\/internalmedicine.7448-21","volume":"60","author":"S Fujii","year":"2021","unstructured":"Fujii, S. et al. Inflammatory myopathy associated with anti-mitochondrial antibody presenting only with respiratory failure. Intern. Med. 60, 3801\u20133804 (2021).","journal-title":"Intern. Med."},{"key":"1188_CR197","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.semarthrit.2017.06.004","volume":"47","author":"J Albayda","year":"2018","unstructured":"Albayda, J. et al. Inflammatory myopathy associated with anti-mitochondrial antibodies: a distinct phenotype with cardiac involvement. Semin. Arthritis Rheum. 47, 552\u2013556 (2018).","journal-title":"Semin. Arthritis Rheum."},{"key":"1188_CR198","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/mus.26731","volume":"61","author":"S Minamiyama","year":"2020","unstructured":"Minamiyama, S. et al. Thigh muscle MRI findings in myopathy associated with anti-mitochondrial antibody. Muscle Nerve 61, 81\u201387 (2020).","journal-title":"Muscle Nerve"},{"key":"1188_CR199","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1016\/j.amjmed.2023.10.009","volume":"137","author":"K Ishizuka","year":"2024","unstructured":"Ishizuka, K. & Ohira, Y. Antimitochondrial antibody-positive myositis. Am. J. Med. 137, e38\u2013e39 (2024).","journal-title":"Am. J. Med."},{"key":"1188_CR200","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1093\/rheumatology\/kez406","volume":"59","author":"Z Betteridge","year":"2020","unstructured":"Betteridge, Z. et al. Identification of a novel autoantigen eukaryotic initiation factor 3 associated with polymyositis. Rheumatology 59, 1026\u20131030 (2020).","journal-title":"Rheumatology"},{"key":"1188_CR201","doi-asserted-by":"publisher","first-page":"1158768","DOI":"10.3389\/fmed.2023.1158768","volume":"10","author":"G La Rocca","year":"2023","unstructured":"La Rocca, G. et al. Targeting intracellular pathways in idiopathic inflammatory myopathies: a narrative review. Front. Med. 10, 1158768 (2023).","journal-title":"Front. Med."},{"key":"1188_CR202","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1097\/BOR.0000000000000749","volume":"32","author":"L Gupta","year":"2020","unstructured":"Gupta, L. & Chinoy, H. Monitoring disease activity and damage in adult and juvenile idiopathic inflammatory myopathy. Curr. Opin. Rheumatol. 32, 553\u2013561 (2020).","journal-title":"Curr. Opin. Rheumatol."},{"key":"1188_CR203","first-page":"1","volume":"82","author":"PR do Vale Pascoal Rodrigues","year":"2024","unstructured":"do Vale Pascoal Rodrigues, P. R. et al. Triple-seronegative myasthenia gravis: clinical and epidemiological characteristics. Arq. Neuropsiquiatr. 82, 1\u20137 (2024).","journal-title":"Arq. Neuropsiquiatr."},{"key":"1188_CR204","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1136\/annrheumdis-2015-208094","volume":"75","author":"G Wigerblad","year":"2016","unstructured":"Wigerblad, G. et al. Autoantibodies to citrullinated proteins induce joint pain independent of inflammation via a chemokine-dependent mechanism. Ann. Rheum. Dis. 75, 730\u2013738 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"1188_CR205","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001228","volume":"7","author":"A Catrina","year":"2021","unstructured":"Catrina, A., Krishnamurthy, A. & Rethi, B. Current view on the pathogenic role of anti-citrullinated protein antibodies in rheumatoid arthritis. RMD Open\u00a07, e001228 (2021).","journal-title":"RMD Open"},{"key":"1188_CR206","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.resinv.2018.07.007","volume":"56","author":"S Sakamoto","year":"2018","unstructured":"Sakamoto, S. et al. Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis. Respir. Investig. 56, 464\u2013472 (2018).","journal-title":"Respir. Investig."},{"key":"1188_CR207","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1002\/acr.21728","volume":"64","author":"H Cao","year":"2012","unstructured":"Cao, H. et al. Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody. Arthritis Care Res. 64, 1602\u20131610 (2012).","journal-title":"Arthritis Care Res."},{"key":"1188_CR208","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/bjd.14882","volume":"176","author":"T Matsushita","year":"2017","unstructured":"Matsushita, T. et al. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis. Br. J. Dermatol. 176, 395\u2013402 (2017).","journal-title":"Br. J. Dermatol."},{"key":"1188_CR209","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1093\/rheumatology\/ker408","volume":"51","author":"Y Muro","year":"2012","unstructured":"Muro, Y., Sugiura, K., Hoshino, K. & Akiyama, M. Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM\/interstitial lung disease during disease remission. Rheumatology 51, 800\u2013804 (2012).","journal-title":"Rheumatology"},{"key":"1188_CR210","first-page":"309","volume":"41","author":"E Tiniakou","year":"2023","unstructured":"Tiniakou, E. et al. Anti-MDA5-positive dermatomyositis and remission in a single referral centre population. Clin. Exp. Rheumatol. 41, 309\u2013315 (2023).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1188_CR211","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1002\/acr.21992","volume":"65","author":"JC Hall","year":"2013","unstructured":"Hall, J. C. et al. Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res. 65, 1307\u20131315 (2013).","journal-title":"Arthritis Care Res."},{"key":"1188_CR212","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.12998\/wjcc.v11.i15.3552","volume":"11","author":"B-H Chen","year":"2023","unstructured":"Chen, B.-H., Zhu, X.-M., Xie, L. & Hu, H.-Q. Immune-mediated necrotizing myopathy: report of two cases. World J. Clin. Cases. 11, 3552\u20133559 (2023).","journal-title":"World J. Clin. Cases."},{"key":"1188_CR213","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1002\/art.30344","volume":"63","author":"O Benveniste","year":"2011","unstructured":"Benveniste, O. et al. Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum. 63, 1961\u20131971 (2011).","journal-title":"Arthritis Rheum."},{"key":"1188_CR214","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s10238-024-01384-2","volume":"24","author":"R Liu","year":"2024","unstructured":"Liu, R. et al. Pathogenic role and clinical significance of neutrophils and neutrophil extracellular traps in idiopathic inflammatory myopathies. Clin. Exp. Med. 24, 115 (2024).","journal-title":"Clin. Exp. Med."},{"key":"1188_CR215","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.12955","volume":"31","author":"L Bolko","year":"2021","unstructured":"Bolko, L. et al. The role of interferons type I, II and III in myositis: a review. Brain Pathol. 31, e12955 (2021).","journal-title":"Brain Pathol."},{"key":"1188_CR216","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s10067-017-3799-y","volume":"37","author":"Y Peng","year":"2018","unstructured":"Peng, Y., Zhang, S., Zhao, Y., Liu, Y. & Yan, B. Neutrophil extracellular traps may contribute to interstitial lung disease associated with anti-MDA5 autoantibody positive dermatomyositis. Clin. Rheumatol. 37, 107\u2013115 (2018).","journal-title":"Clin. Rheumatol."},{"key":"1188_CR217","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.134189","volume":"5","author":"N Seto","year":"2020","unstructured":"Seto, N. et al. Neutrophil dysregulation is pathogenic in idiopathic inflammatory myopathies. JCI Insight 5, e134189 (2020).","journal-title":"JCI Insight"},{"key":"1188_CR218","doi-asserted-by":"publisher","first-page":"802499","DOI":"10.3389\/fimmu.2022.802499","volume":"13","author":"L Zhao","year":"2022","unstructured":"Zhao, L. et al. Machine learning algorithms identify clinical subtypes and cancer in anti-TIF1\u03b3+ myositis: a longitudinal study of 87 patients. Front. Immunol. 13, 802499 (2022).","journal-title":"Front. Immunol."},{"key":"1188_CR219","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/cei.12319","volume":"177","author":"S Zhang","year":"2014","unstructured":"Zhang, S. et al. Enhanced formation and impaired degradation of neutrophil extracellular traps in dermatomyositis and polymyositis: a potential contributor to interstitial lung disease complications. Clin. Exp. Immunol. 177, 134\u2013141 (2014).","journal-title":"Clin. Exp. Immunol."},{"key":"1188_CR220","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/ana.24902","volume":"81","author":"L Arouche-Delaperche","year":"2017","unstructured":"Arouche-Delaperche, L. et al. Pathogenic role of anti-signal recognition protein and anti-3-Hydroxy-3-methylglutaryl-CoA reductase antibodies in necrotizing myopathies: myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies. Ann. Neurol. 81, 538\u2013548 (2017).","journal-title":"Ann. Neurol."},{"key":"1188_CR221","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1136\/annrheumdis-2018-213518","volume":"78","author":"C Bergua","year":"2019","unstructured":"Bergua, C. et al. In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy. Ann. Rheum. Dis. 78, 131\u2013139 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"1188_CR222","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/art.1780230802","volume":"23","author":"M Nishikai","year":"1980","unstructured":"Nishikai, M. & Reichlin, M. Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis. Characterization of the Jo-1 antibody system. Arthritis Rheum. 23, 881\u2013888 (1980).","journal-title":"Arthritis Rheum."},{"key":"1188_CR223","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/304177a0","volume":"304","author":"MB Mathews","year":"1983","unstructured":"Mathews, M. B. & Bernstein, R. M. Myositis autoantibody inhibits histidyl-tRNA synthetase: a model for autoimmunity. Nature 304, 177\u2013179 (1983).","journal-title":"Nature"},{"key":"1188_CR224","doi-asserted-by":"publisher","first-page":"848","DOI":"10.3389\/fimmu.2019.00848","volume":"10","author":"M Mahler","year":"2019","unstructured":"Mahler, M. et al. Comparison of three immunoassays for the detection of myositis specific antibodies. Front. Immunol. 10, 848 (2019).","journal-title":"Front. Immunol."},{"key":"1188_CR225","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.nmd.2022.05.011","volume":"32","author":"J Damoiseaux","year":"2022","unstructured":"Damoiseaux, J., Mammen, A. L., Piette, Y., Benveniste, O. & Allenbach, Y. 256th ENMC international workshop: myositis specific and associated autoantibodies (MSA-ab): Amsterdam, The Netherlands, 8\u201310 October 2021. Neuromuscul. Disord. 32, 594\u2013608 (2022).","journal-title":"Neuromuscul. Disord."},{"key":"1188_CR226","doi-asserted-by":"publisher","first-page":"975939","DOI":"10.3389\/fimmu.2022.975939","volume":"13","author":"A Loganathan","year":"2022","unstructured":"Loganathan, A. et al. The use of ELISA is comparable to immunoprecipitation in the detection of selected myositis-specific autoantibodies in a European population. Front. Immunol. 13, 975939 (2022).","journal-title":"Front. Immunol."},{"key":"1188_CR227","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1093\/rheumatology\/keq281","volume":"49","author":"A Ghirardello","year":"2010","unstructured":"Ghirardello, A. et al. Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay. Rheumatology 49, 2370\u20132374 (2010).","journal-title":"Rheumatology"},{"key":"1188_CR228","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13075-020-02210-2","volume":"22","author":"SL Tansley","year":"2020","unstructured":"Tansley, S. L. et al. The promise, perceptions, and pitfalls of immunoassays for autoantibody testing in myositis. Arthritis Res. Ther. 22, 117 (2020).","journal-title":"Arthritis Res. Ther."},{"key":"1188_CR229","doi-asserted-by":"publisher","first-page":"112661","DOI":"10.1016\/j.jim.2019.112661","volume":"474","author":"I Cavazzana","year":"2019","unstructured":"Cavazzana, I. et al. Evaluation of a novel particle-based assay for detection of autoantibodies in idiopathic inflammatory myopathies. J. Immunol. Methods 474, 112661 (2019).","journal-title":"J. Immunol. Methods"},{"key":"1188_CR230","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213153","volume":"78","author":"M Mahler","year":"2019","unstructured":"Mahler, M. & Fritzler, M. J. Detection of myositis-specific antibodies: additional notes. Ann. Rheum. Dis. 78, e29 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"1188_CR231","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1136\/annrheumdis-2018-214690","volume":"78","author":"F Espinosa-Ortega","year":"2019","unstructured":"Espinosa-Ortega, F. et al. Comparison of autoantibody specificities tested by a line blot assay and immunoprecipitation-based algorithm in patients with idiopathic inflammatory myopathies. Ann. Rheum. Dis. 78, 858\u2013860 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"1188_CR232","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1093\/rheumatology\/keaa021","volume":"59","author":"SL Tansley","year":"2020","unstructured":"Tansley, S. L., Li, D., Betteridge, Z. E. & McHugh, N. J. The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity. Rheumatology 59, 2109\u20132114 (2020).","journal-title":"Rheumatology"},{"key":"1188_CR233","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/imj.16350","volume":"54","author":"HT Anderson","year":"2024","unstructured":"Anderson, H. T., O\u2019Donnell, J. L., Tustin, P. & Steele, R. Diagnosis and subtyping of idiopathic inflammatory myopathies: caution required in the use of myositis autoantibodies. Intern. Med. J. 54, 682\u2013686 (2024).","journal-title":"Intern. Med. J."},{"key":"1188_CR234","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1002\/mus.28050","volume":"69","author":"YC Chang","year":"2024","unstructured":"Chang, Y. C., Yang, L. & Budhram, A. Positive predictive value of myositis antibody line blot testing in patients with suspected idiopathic inflammatory myopathy. Muscle Nerve 69, 626\u2013630 (2024).","journal-title":"Muscle Nerve"},{"key":"1188_CR235","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jim.2016.02.017","volume":"433","author":"I Cavazzana","year":"2016","unstructured":"Cavazzana, I. et al. Testing for myositis specific autoantibodies: comparison between line blot and immunoprecipitation assays in 57 myositis sera. J. Immunol. Methods 433, 1\u20135 (2016).","journal-title":"J. Immunol. Methods"},{"key":"1188_CR236","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0085062","volume":"9","author":"R Nakashima","year":"2014","unstructured":"Nakashima, R. et al. The multicenter study of a new assay for simultaneous detection of multiple anti-aminoacyl-tRNA synthetases in myositis and interstitial pneumonia. PLoS ONE 9, e85062 (2014).","journal-title":"PLoS ONE"},{"key":"1188_CR237","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0154285","volume":"11","author":"S Sato","year":"2016","unstructured":"Sato, S. et al. Clinical utility of an enzyme-linked immunosorbent assay for detecting anti-melanoma differentiation-associated gene 5 autoantibodies. PLoS ONE 11, e0154285 (2016).","journal-title":"PLoS ONE"},{"key":"1188_CR238","doi-asserted-by":"publisher","first-page":"856815","DOI":"10.1155\/2013\/856815","volume":"2013","author":"Y Muro","year":"2013","unstructured":"Muro, Y., Sugiura, K. & Akiyama, M. A new ELISA for dermatomyositis autoantibodies: rapid introduction of autoantigen cDNA to recombinant assays for autoantibody measurement. Clin. Dev. Immunol. 2013, 856815 (2013).","journal-title":"Clin. Dev. Immunol."},{"key":"1188_CR239","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.mex.2017.03.002","volume":"4","author":"T Waritani","year":"2017","unstructured":"Waritani, T., Chang, J., McKinney, B. & Terato, K. An ELISA protocol to improve the accuracy and reliability of serological antibody assays. MethodsX 4, 153\u2013165 (2017).","journal-title":"MethodsX"},{"key":"1188_CR240","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.pathol.2016.03.012","volume":"48","author":"C Bundell","year":"2016","unstructured":"Bundell, C., Rojana-Udomsart, A., Mastaglia, F., Hollingsworth, P. & McLean-Tooke, A. Diagnostic performance of a commercial immunoblot assay for myositis antibody testing. Pathology 48, 363\u2013366 (2016).","journal-title":"Pathology"},{"key":"1188_CR241","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212915","volume":"78","author":"J-B Vulsteke","year":"2019","unstructured":"Vulsteke, J.-B. et al. Detection of myositis-specific antibodies. Ann. Rheum. Dis. 78, e7 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"1188_CR242","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1093\/rheumatology\/kez092","volume":"58","author":"M Richards","year":"2019","unstructured":"Richards, M. et al. Autoantibodies to Mi-2 alpha and Mi-2 beta in patients with idiopathic inflammatory myopathy. Rheumatology 58, 1655\u20131661 (2019).","journal-title":"Rheumatology"},{"key":"1188_CR243","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1002\/art.40320","volume":"69","author":"IE Lundberg","year":"2017","unstructured":"Lundberg, I. E. et al. 2017 European League Against Rheumatism\/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. Arthritis Rheumatol. 69, 2271\u20132282 (2017).","journal-title":"Arthritis Rheumatol."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-024-01188-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-024-01188-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-024-01188-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T14:03:07Z","timestamp":1734703387000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-024-01188-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,28]]},"references-count":243,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["1188"],"URL":"https:\/\/doi.org\/10.1038\/s41584-024-01188-4","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,28]]},"assertion":[{"value":"28 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}